arrow
M

Moritz Binder

mayo clinic
H指数:28
被引数:2,840

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Biomarkers of cellular senescence and their association with frailty, clinical outcomes, and survival in multiple myeloma

细胞衰老的生物标志物及其与多发性骨髓瘤中虚弱、临床结局和生存期的关联

2026-10-300
OAAI
Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival

1q染色体增益定义了AL淀粉样变性中一种浆细胞占优势的不良风险亚型,其长期生存率较差

2026-08-260
PRE
High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients

达雷木单抗治疗的新诊断多发性骨髓瘤患者中缺铁的高发生率

2026-08-210
PRE
Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity

预防性地塞米松在绝对淋巴细胞扩增时并不能减轻与免疫效应细胞相关的迟发性神经毒性的风险或无事件生存期

2026-08-100
OA
Self-Reported Geriatric Impairments and Treatment Toxicity in Older Patients with Multiple Myeloma–A Single Center Prospective Study

老年多发性骨髓瘤患者自报的老年功能损害和治疗毒性的单中心前瞻性研究

2026-07-300
OA
Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma

移植后可测量残留病灶阴性的预测因素及其对多发性骨髓瘤临床结局的影响

2026-07-290
OA
Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma
Leukemia
IF13.4
2026-07-210
PRE
Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma

达拉妥单抗、伊沙佐米和来那度胺联合或不联合地塞米松治疗新诊断骨髓瘤的初始疗法

2026-07-180
OA
Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement

中枢神经系统受累的多发性骨髓瘤的临床病程、危险因素和治疗效果

2026-06-260
OA
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma

接受Ciltacabtagene-Autoleucel治疗的复发/难治性多发性骨髓瘤患者的早期治疗失败

2026-06-250
PRE
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma

自体干细胞移植治疗多发性骨髓瘤后继发血液系统恶性肿瘤的特征与结局

2026-06-230
OAAI
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype

AL型淀粉样变性接受抗浆细胞疗法后肾脏反应的预测因素:基线血清游离轻链水平和轻链亚型的影响

2026-05-100
PRE
Diagnosis and management of immune effector cell-associated enterocolitis (IEC-EC) following ciltacabtagene autoleucel

免疫效应细胞相关肠结肠炎(IEC-EC)的诊断与管理:基于cilta-cabtagene autoleucel的应用

2026-04-170
OAAI
Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL Amyloidosis

系统性AL淀粉样变性胃肠疾病负担和生存的影响因素

2026-04-130
OAAI
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma

诊断时升高的非克隆性骨髓浆细胞分数与多发性骨髓瘤的预后改善相关

2026-01-030
OAAI
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma

免疫效应细胞相关迟发性神经毒性的临床病程、危险因素及缓解策略:ciltacabtagene autoleucel CAR-T在多发性骨髓瘤中的应用

2025-12-310
OAAI
Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia

t(11;14)初发细胞遗传学异常及诊断时多种高危细胞遗传学累积效应对原发性浆细胞白血病预后的影响

2025-12-270
OAAI
AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy

AL淀粉样变性:CAR-T细胞疗法的真实世界经验

2025-10-170
OAAI
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma

轻链型多发性骨髓瘤的临床特征、治疗反应及预后

2025-10-040
PRE